BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia

MedStar Georgetown University Hospital, Washington D.C.

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

Wake Forest University at Clemmons, Clemmons

Wake Forest University Health Sciences, Winston-Salem

Wake Forest Baptist Health - Wilkes Medical Center, Wilkesboro

Northwestern University, Chicago

Washington University School of Medicine, St Louis

Siteman Cancer Center-South County, St Louis

Siteman Cancer Center at Christian Hospital, St Louis

Siteman Cancer Center at West County Hospital, Creve Coeur

Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters

University of Kansas Cancer Center - Lee's Summit, Lee's Summit

University Health Truman Medical Center, Kansas City

University of Kansas Cancer Center at North Kansas City Hospital, North Kansas City

University of Kansas Cancer Center - North, Kansas City

Lawrence Memorial Hospital, Lawrence

The University of Kansas Cancer Center - Olathe, Olathe

University of Kansas Cancer Center, Kansas City

University of Kansas Hospital-Westwood Cancer Center, Westwood

University of Kansas Cancer Center-Overland Park, Overland Park

University of Kansas Health System Saint Francis Campus, Topeka

Mercy Hospital Pittsburg, Pittsburg

Salina Regional Health Center, Salina

HaysMed, Hays

University of Oklahoma Health Sciences Center, Oklahoma City

Smilow Cancer Hospital Care Center at Greenwich, Greenwich

Smilow Cancer Hospital Care Center at Saint Francis, Hartford

Yale University, New Haven

Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon